Teleflex Incorporated
TFX Healthcare Medical Instruments & Supplies
Teleflex Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 17.2% from fiscal 2024.
- Revenue
- +28.9%
- EPS
- −17.3%
- Free cash flow
- +220.1%
- Total debt
- +47.7%
Quarter to June 2026, against a year earlier
Follow TFX
Alert me
Teleflex Incorporated (TFX) EV/Sales
As of 5 November 2026, Teleflex Incorporated (TFX) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 2.9× (February 2015) to 9.0× (April 2021); the current reading is higher than 26% of that period. That is above the Medical Instruments & Supplies industry median of 2.8× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.9× | (32.53%) |
| FY2024 | 5.7× | 27.66% |
| FY2023 | 4.5× | (4.59%) |
| FY2022 | 4.7× | (21.14%) |
| FY2021 | 6.0× | (28.69%) |
| FY2020 | 8.4× | 14.33% |
| FY2019 | 7.3× | 31.68% |
| FY2018 | 5.6× | (10.82%) |
| FY2017 | 6.2× | 57.92% |
| FY2016 | 3.9× | 15.53% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.6× | (0.36%) |
| Mar 2026 | 3.6× | (7.60%) |
| Dec 2025 | 3.9× | (6.63%) |
| Sep 2025 | 4.1× | 3.77% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVST Envista Holdings Corporation compare | 1.5× |
| MMED MiniMed Group, Inc. compare | 1.6× |
| AVTR Avantor, Inc. compare | 2.0× |
| BLCO Bausch + Lomb Corporation compare | 2.2× |
| ICUI ICU Medical, Inc. compare | 2.3× |
| ATR AptarGroup, Inc. compare | 2.6× |
| MMSI Merit Medical Systems, Inc. compare | 3.5× |
| TFX Teleflex Incorporated | 4.1× |
| PLSE Pulse Biosciences, Inc compare | 2,578× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on TFX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement